Proarrhythmic major adverse cardiac events with donepezil: A systematic review with meta‐analysis
Journal of the American Geriatrics Society · 2024
DOI: 10.1111/jgs.18909 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of the American Geriatrics Society, 2024. Verfasst von Tina Nham und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Geriatrics, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Donepezil, Cholinesterase Inhibitors, Alzheimer Disease. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ontario Ministry of Health and Long-Term Care.
Abstract (Originalsprache)
Background
Cholinesterase inhibitors (ChEIs) are regularly used in Alzheimer's disease. Of the three ChEIs approved for dementia, donepezil is among the most prescribed drugs in the United States with nearly 6 million prescriptions in 2020; however, it is classified as a “known risk” QT interval‐prolonging medication (QTPmed). Given this claim is derived from observational data including single case reports, we aimed to evaluate high‐quality literature on the frequency and nature of proarrhythmic major adverse cardiac events (MACE) associated with donepezil.
Methods
We searched Medline, Embase, International Pharmaceutical Abstracts, and Cochrane Central from 1996 onwards for randomized controlled trials (RCTs) involving patients age ≥18 years comparing donepezil to placebo. The MACE composite included mortality, sudden cardiac death, non‐fatal cardiac arrest, Torsades de pointes, ventricular tachyarrhythmia, seizure or syncope. Random‐effects meta‐analyses were performed with a treatment‐arm continuity correction for single and double zero event studies.
Results
Sixty RCTs ( n = 12,463) were included. Twenty‐five of 60 trials ( n = 5886) investigated participants with Alzheimer's disease and 33 trials monitored electrocardiogram data. The mean follow‐up duration was 31 weeks (SD = 36). Mortality was the most commonly reported MACE (252/331, 75.8% events), the remainder were syncope or seizures, with no arrhythmia events. There was no increased risk of MACE with exposure to donepezil compared to placebo (risk ratio [RR] 1.08, 95% CI 0.88–1.33, I 2 = 0%) and this was consistent in the subgroup analysis of trials including participants with cardiovascular morbidities (RR 1.14, 95% CI 0.88–1.47). Subgroup analysis suggested a trend toward more events with donepezil with follow‐up ≥52 weeks (RR: 1.32, 0.98–1.79).
Conclusions
This systematic review with meta‐analysis found donepezil may not be arrhythmogenic. Donepezil was not associated with mortality, ventricular arrhythmias, seizure or syncope, although longer durations of therapy need more study. Further research to clarify actual clinical outcomes related to QTPmed is important to inform prescribing practices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Geriatrics, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- Clinical Pharmacology & Toxicology Research Group, St. Joseph's Healthcare, Hamilton, Ontario, Canada.
- Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Department of Biomedical and Molecular Sciences, Queens University, Kingston, Ontario, Canada.
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
- Biostatistics Unit, Father Sean O'Sullivan Research Centre, St Joseph's Healthcare, Hamilton, Ontario, Canada.
ORCID-Profile: Michael Cristian Garcia, Jessyca Matos Silva, Tyler Schneider, Jiawen Deng, Lawrence Mbuagbaw, Anne Holbrook
Förderung
- Ontario Ministry of Health and Long-Term Care
Zitieren
APA
Nham, T., Garcia, M. C., Tsang, K. J., Silva, J. M., Schneider, T., Deng, J., Lohit, S., Mbuagbaw, L., & Holbrook, A. (2024). Proarrhythmic major adverse cardiac events with donepezil: A systematic review with meta‐analysis. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.18909
Vancouver
Nham T, Garcia MC, Tsang KJ, Silva JM, Schneider T, Deng J, et al. Proarrhythmic major adverse cardiac events with donepezil: A systematic review with meta‐analysis. Journal of the American Geriatrics Society. 2024. doi:10.1111/jgs.18909
BibTeX
@article{Nham2024,
author = {Nham, Tina and Garcia, Michael Cristian and Tsang, Kai La Jennifer and Silva, Jessyca Matos and Schneider, Tyler and Deng, Jiawen and Lohit, Simran and Mbuagbaw, Lawrence and Holbrook, Anne},
title = {Proarrhythmic major adverse cardiac events with donepezil: A systematic review with meta‐analysis},
journal = {Journal of the American Geriatrics Society},
year = {2024},
doi = {10.1111/jgs.18909}
}
EUVIMED